

**Question for written answer E-003743/2015
to the Commission**

Rule 130

Joëlle Mélin (NI), Jean-François Jalkh (NI), Mireille D'Ornano (NI), Sylvie Goddyn (NI) and Marie-Christine Arnautu (NI)

Subject: Therapeutic innovation and access to medicines

Research in the field of health constitutes one of the most innovative sectors in Europe, and is a source of growth and jobs.

Given that the costs of treatment fall within the ambit of national policies governing access to care and that the use of medicinal therapies may prevent the need for more serious treatments and contribute to the well-being of patients:

1. In order to support innovation, should not the price of a medicine incorporate fair remuneration for the research laboratories?
2. In order to support therapeutic advances, to promote a scientific approach that spans different research areas and to increase the speed at which new medicines can be placed on the market, would it not be appropriate to relaunch the Horizon 2020 programme, which has recently been undermined by the investment projects of the Juncker plan?